Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT04509817
Other study ID # GH201802
Secondary ID KHNMCOH 2017-12-
Status Not yet recruiting
Phase N/A
First received
Last updated
Start date November 1, 2020
Est. completion date March 31, 2022

Study information

Verified date October 2020
Source China Academy of Chinese Medical Sciences
Contact Chunlan Jin, MD
Phone +8613051207195
Email kimcl@sina.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study is an international multicenter, pilot randomized, assessor-blind, controlled trial, which is aimed to preliminarily investigate the efficacy and safety of acupuncture on oligomenorrhea due to polycystic ovary syndrome (PCOS).


Description:

A total of 60 subjects will be recruited and randomly allocated into experimental or control group with 30 subjects respectively. The subjects in experimental group will receive a standardized acupuncture treatment plus usual care, whereas the ones in control group will be managed only with usual care.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 60
Est. completion date March 31, 2022
Est. primary completion date December 31, 2021
Accepts healthy volunteers No
Gender Female
Age group 20 Years to 40 Years
Eligibility Inclusion Criteria: - Oligomenorrhea (menstrual cycle> 35 days or less than 8 cycles per year) plus at least one of the following two criteria; hyperandrogenism (clinical, biochemical, or both) and/or polycystic ovarian morphologic features [12 or more antral follicles (2 to 9 mm in diameter) in either ovary, an ovarian volume that is greater than 10 ml in either ovary, or both] - 20-40 years of age - Voluntary agreement to participate in this trial Exclusion Criteria: - Pregnancy, labor or breastfeeding within the past 3 months - Intake of oral contraceptive or ovulation inducing agent within the past 3 months - Severe oligomenorrhea with menstrual period over 3 months - Menstruation during more than 8 days - Premature ovarian failure - Resistant thyroid disease, Cushing's disease, congenital adrenal hyperplasia, or hyperprolactinemia - Ovarian tumor or adrenal tumor that cause hyperandrogenemia - Hemorrhagic disease - Severe cardiac, pulmonary, hepatic, or renal diseases, central nervous system disorders, or intake of psychoactive drug - Acupuncture treatment within the past one month - Participation in other clinical trial within the past 3 months - Other conditions judged to be inappropriate for the clinical study by the investigators

Study Design


Related Conditions & MeSH terms


Intervention

Device:
Acupuncture+Usual care
Acupuncture intervention Disposable, sterilized needles (0.25×40 mm and 0.30×50 mm) will be used and selected acupoints will include GV20, CV4, and bilateral BL32, ST25, ST29, EX-CA1, LI4, LR3, SP6, SP9. Subject will be prone position first and BL32 will be inserted with an angle of 30-45° in an inferomedial direction and a depth of 30-50 mm. Once the subject has a needle sensation ('De-qi'), the needle will be removed immediately. Then the subject will be supine position, and GV20, CV4, ST25, ST29, EX-CA1, LI4, LR3, SP6, SP9 will be needled with a depth of 10-40mm. After subject feel 'De-qi', the needles will be placed for 20 min to maintain the stimulation. Usual care intervention The subjects will receive the health advice including diet with regular meal, enough sleep, and appropriate exercise. Behavioral: Usual care Usual care intervention The subjects will receive the health advice including diet with regular meal, enough sleep, and appropriate exercise.
Behavioral:
Usual care
Usual care intervention The subjects will receive the health advice

Locations

Country Name City State
China Dongzhimen Hospital Beijing Beijing
China Institute of acupuncture and moxibustion Beijing Beijing
Korea, Republic of Kyung Hee University Hospital at Gangdong Seoul

Sponsors (4)

Lead Sponsor Collaborator
China Academy of Chinese Medical Sciences Dongzhimen Hospital, Beijing, Korea Institute of Oriental Medicine, Kyung Hee University Hospital at Gangdong

Countries where clinical trial is conducted

China,  Korea, Republic of, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in Menstrual Frequency (cycles/month) Menstrual cycle improvement will be assessed by menstrual frequency (cycle/month). Baseline, post-intervention (16 weeks), follow-up (32 weeks)
Secondary Change in Menstrual Period Menstrual period is assessed in days from the 1st day of menstruation cycle to 1st day of the next menstruation cycle. Baseline, post-intervention (16 weeks), follow-up (32 weeks)
Secondary Change in Estradiol (E2) Change in the level of serum estradiol in pg/mL Baseline, post-intervention (16 weeks), follow-up (32 weeks)
Secondary Change in Luteinizing Hormone (LH) Change in the level of serum luteinizing hormone (LH) in mIU/mL Baseline, post-intervention (16 weeks), follow-up (32 weeks)
Secondary Change in Serum Follicle Stimulating Hormone (FSH) Change in the level of serum follicle stimulating hormone (FSH) in mIU/mL Baseline, post-intervention (16 weeks), follow-up (32 weeks)
Secondary Change in Free Testosterone (T) Change in the level of serum free testosterone (T) in ng/mL Baseline, post-intervention (16 weeks), follow-up (32 weeks)
Secondary Change in LH/FSH Ratio The ratio is calculated based on the value of LH and FSH. Baseline, post-intervention (16 weeks), follow-up (32 weeks)
Secondary Change in Antral Follicle Count (AFC) in the Ovary and Ovarian Volume Change in the number of antral follicles of the ovary and ovarian volume by ultrasound imaging. Baseline, post-intervention (16 weeks), follow-up (32 weeks)
Secondary Change in Body mass index (BMI) Body Mass Index (BMI) is defined as the body weight divided by the square of height, and expressed in kg/m2. Baseline, post-intervention (16 weeks), follow-up (32 weeks)
Secondary Change in Waist Hip Ratio (WHR) The ratio is calculated based on the length of waist and hip. Baseline, post-intervention (16 weeks), follow-up (32 weeks)
Secondary Change in acne severity evaluated by Pillsbury acne grading system Acne severity is assessed by Pillsbury acne grading system. The grade of Pillsbury acne grading system ranges from 0 to 4. The high-scored grade means the more severe acne (i.e., grade 0 is considered to be normal, and grade 4 is considered severe). Baseline, post-intervention (16 weeks), follow-up (32 weeks)
Secondary Change in quality of life evaluated by the 36-Item Short Form Health Survey (SF-36) SF-36 is a 36-item, patient-reported survey of patient health, which consists of eight sections. The score of SF36 ranges from 0 to 100. The higher the score, the less disability, i.e., a score of 0 is equivalent to maximum disability and a score of 100 is equivalent to no disability. Baseline, post-intervention (16 weeks), follow-up (32 weeks)
Secondary Adverse events All expected or unexpected adverse events in both groups will be measured at every study visit.
Assessment of severity: mild, moderate, severe
Assessment of relation: definitely related, probably related, possibly related, probably not related, definitely not related, unknown.
up to 32 weeks
Secondary Incidence of abnormal complete blood count The incidence of patients with abnormal complete blood count which includes the white blood cells count in ×10^9/L, the red blood cells count in ×10^12/L, platelets count in number ×10^9/L, and hemoglobin in g/L, and hematocrit in %. Baseline, post-intervention (16 weeks), follow-up (32 weeks)
Secondary Incidence of abnormal erythrocyte sedimentation rate Incidence of patients with abnormal erythrocyte sedimentation rate in mm/h. Baseline, post-intervention (16 weeks), follow-up (32 weeks)
Secondary Incidence of abnormal renal function Incidence of abnormal lactate dehydrogenase and creatine phosphokinase. Incidence of patients with abnormal lactate dehydrogenase in U/L, and creatinine phosphokinase in U/L. Baseline, post-intervention (16 weeks), follow-up (32 weeks)
Secondary Incidence of abnormal liver function Incidence of patients with abnormal liver function evaluated by serum aspartate aminotransferase in U/L, alanine aminotransferase in U/L, and ?-glutamyl-transpeptidase in U/L, alkaline phosphatase U/L, total protein in g/L, and albumin in g/L. Baseline, post-intervention (16 weeks), follow-up (32 weeks)
See also
  Status Clinical Trial Phase
Completed NCT03142633 - MicroRNA as Biomarkers for Development of Metabolic Syndrome in Women With Polycystic Ovary Syndrome
Completed NCT06158932 - A Single Group Study to Evaluate the Effects of a Myo-Inositol and D-Chiro Inositol Supplement on Symptoms Associated With Polycystic Ovary Syndrome and Hormone Imbalance N/A
Completed NCT03644524 - Heat Therapy and Cardiometabolic Health in Obese Women N/A
Active, not recruiting NCT02500147 - Metformin for Ectopic Fat Deposition and Metabolic Markers in Polycystic Ovary Syndrome (PCOS) Phase 4
Completed NCT04932070 - Berberine and Polycystic Ovary Syndrome N/A
Suspended NCT03652987 - Endocrine and Menstrual Disturbances in Women With Polycystic Ovary Syndrome (PCOS)
Completed NCT03480022 - Liraglutide 3mg (Saxenda) on Weight, Body Composition, Hormonal and Metabolic Parameters in Obese Women With PCOS Phase 3
Active, not recruiting NCT03043924 - Functional Study of the Hypothalamus in Magnetic Resonance Imaging (MRI) in Polycystic Ovary Syndrome (PCOS) N/A
Completed NCT05246306 - Aerobic Capacity and Physical Fitness Level of Adolescents With PCOS
Completed NCT05981742 - Effects of Combined Metformin and Cabergoline in Comparison With Metformin Only Therapy on Ovarian and Hormonal Activities in Iraqi Patients With PCOS Phase 2
Completed NCT05702957 - Letrozole vs Clomiphene Citrate for Induction of Ovulation in Women With Polycystic Ovarian Syndrome Phase 2/Phase 3
Completed NCT05029492 - Effect of Visceral Manipulation on PCOS N/A
Not yet recruiting NCT02255578 - Endobarrier Treatment in Women With PCOS Phase 3
Completed NCT02924025 - Motivational Interviewing as an Intervention for PCOS N/A
Completed NCT02098668 - Mathematical Model for the Human Menstrual Cycle, Endocrinological Diseases and Fertility Treatment-PAEON N/A
Withdrawn NCT01638988 - Clomifene Citrate Versus Metformin in First-line Treatment of Infertility in Patients With Polycystic Ovary Syndrome and a Resistance to Insulin Phase 3
Not yet recruiting NCT00883259 - Metformin and Gestational Diabetes in High-risk Patients: a RCTs Phase 4
Completed NCT01462864 - Development of a Structured Education Programme for Women With Polycystic Ovary Syndrome N/A
Recruiting NCT01431352 - Letrozole Versus Chinese Herbal Medicine on Polycystic Ovary Syndrome (PCOS) N/A
Completed NCT00989781 - Mechanisms of Increased Androgen Production Among Women With Polycystic Ovary Syndrome N/A